{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:05:35Z","timestamp":1779426335843,"version":"3.53.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"STI2030-Major Projects","award":["STI2030-Major Projects (2022ZD0213800)"],"award-info":[{"award-number":["STI2030-Major Projects (2022ZD0213800)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00259-026-07796-4","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T01:59:47Z","timestamp":1772675987000},"page":"4597-4605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["[68Ga]Ga-NOTA-T4 PET\/CT imaging of TROP2 expression in patients with HER2-negative breast cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Yao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoding","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2667-281X","authenticated-orcid":false,"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"7796_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"7796_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010.","journal-title":"Breast"},{"key":"7796_CR3","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206\u201323. https:\/\/doi.org\/10.1093\/annonc\/mdt303.","journal-title":"Ann Oncol"},{"key":"7796_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66.","journal-title":"Nat Rev Clin Oncol"},{"key":"7796_CR5","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348. https:\/\/doi.org\/10.1056\/NEJMra1001389.","journal-title":"N Engl J Med"},{"key":"7796_CR6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in metastatic Triple-Negative breast cancer. N Engl J Med. 2021;384:1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"7796_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/ijc.2910620520","volume":"62","author":"M Fornaro","year":"1995","unstructured":"Fornaro M, Dell\u2019Arciprete R, Stella M, Bucci C, Nutini M, Capri MG, et al. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer. 1995;62:610\u20138. https:\/\/doi.org\/10.1002\/ijc.2910620520.","journal-title":"Int J Cancer"},{"key":"7796_CR8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.21037\/atm-22-5976","volume":"10","author":"Y Wen","year":"2022","unstructured":"Wen Y, Ouyang D, Zou Q, Chen Q, Luo N, He H, et al. A literature review of the promising future of TROP2: a potential drug therapy target. Ann Transl Med. 2022;10:1403. https:\/\/doi.org\/10.21037\/atm-22-5976.","journal-title":"Ann Transl Med"},{"key":"7796_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000522206","volume":"89","author":"D Dum","year":"2022","unstructured":"Dum D, Taherpour N, Menz A, Hoflmayer D, Volkel C, Hinsch A, et al. Trophoblast cell surface antigen 2 expression in human tumors: A tissue microarray study on 18,563 tumors. Pathobiology. 2022;89:245\u201358. https:\/\/doi.org\/10.1159\/000522206.","journal-title":"Pathobiology"},{"key":"7796_CR10","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/emmm.201200222","volume":"4","author":"JC Lin","year":"2012","unstructured":"Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang YL, et al. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med. 2012;4:472\u201385. https:\/\/doi.org\/10.1002\/emmm.201200222.","journal-title":"EMBO Mol Med"},{"key":"7796_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/onc.2012.36","volume":"32","author":"M Trerotola","year":"2013","unstructured":"Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222\u201333. https:\/\/doi.org\/10.1038\/onc.2012.36.","journal-title":"Oncogene"},{"key":"7796_CR12","doi-asserted-by":"publisher","first-page":"200762","DOI":"10.1016\/j.omton.2024.200762","volume":"32","author":"Q Liao","year":"2024","unstructured":"Liao Q, Zhang R, Ou Z, Ye Y, Zeng Q, Wang Y, et al. TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs. Mol Ther Oncol. 2024;32:200762. https:\/\/doi.org\/10.1016\/j.omton.2024.200762.","journal-title":"Mol Ther Oncol"},{"key":"7796_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.ejca.2009.12.019","volume":"46","author":"E Bignotti","year":"2010","unstructured":"Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010;46:944\u201353. https:\/\/doi.org\/10.1016\/j.ejca.2009.12.019.","journal-title":"Eur J Cancer"},{"key":"7796_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3322\/caac.21713","volume":"72","author":"SP Rowe","year":"2022","unstructured":"Rowe SP, Pomper MG. Molecular imaging in oncology: current impact and future directions. CA Cancer J Clin. 2022;72:333\u201352. https:\/\/doi.org\/10.3322\/caac.21713.","journal-title":"CA Cancer J Clin"},{"key":"7796_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/annonc\/mdx053","volume":"28","author":"A Vivot","year":"2017","unstructured":"Vivot A, Jacot J, Zeitoun JD, Ravaud P, Crequit P, Porcher R. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000\u20132015. Ann Oncol. 2017;28:1111\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdx053.","journal-title":"Ann Oncol"},{"key":"7796_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00259-023-06454-3","volume":"51","author":"W Huang","year":"2024","unstructured":"Huang W, Liang C, Zhang Y, Zhang D, An S, Wu Q, et al. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. Eur J Nucl Med Mol Imaging. 2024;51:380\u201394. https:\/\/doi.org\/10.1007\/s00259-023-06454-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7796_CR17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s44321-024-00059-5","volume":"16","author":"W Huang","year":"2024","unstructured":"Huang W, Zhang Y, Cao M, Wu Y, Jiao F, Chu Z, et al. ImmunoPET imaging of Trop2 in patients with solid tumours. EMBO Mol Med. 2024;16:1143\u201361. https:\/\/doi.org\/10.1038\/s44321-024-00059-5.","journal-title":"EMBO Mol Med"},{"key":"7796_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI185408","author":"H Chen","year":"2024","unstructured":"Chen H, Zhao L, Pang Y, Shi J, Gao H, Sun Y, et al. 68Ga-MY6349 PET\/CT imaging to assess Trop2 expression in multiple types of cancer. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI185408.","journal-title":"J Clin Invest"},{"key":"7796_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7796_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","volume":"75","author":"BE Nelson","year":"2024","unstructured":"Nelson BE, Meric-Bernstam F. Leveraging TROP2 Antibody-Drug conjugates in solid tumors. Annu Rev Med. 2024;75:31\u201348. https:\/\/doi.org\/10.1146\/annurev-med-071322-065903.","journal-title":"Annu Rev Med"},{"key":"7796_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12935-018-0589-9","volume":"18","author":"SM Zimmers","year":"2018","unstructured":"Zimmers SM, Browne EP, Williams KE, Jawale RM, Otis CN, Schneider SS, et al. TROP2 methylation and expression in tamoxifen-resistant breast cancer. Cancer Cell Int. 2018;18:94. https:\/\/doi.org\/10.1186\/s12935-018-0589-9.","journal-title":"Cancer Cell Int"},{"key":"7796_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10549-022-06660-x","volume":"194","author":"N Vidula","year":"2022","unstructured":"Vidula N, Yau C, Rugo H. Trophoblast cell surface antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast Cancer Res Treat. 2022;194:569\u201375. https:\/\/doi.org\/10.1007\/s10549-022-06660-x.","journal-title":"Breast Cancer Res Treat"},{"key":"7796_CR23","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab Govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2021;32:1148\u201356. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.002.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"7796_CR24","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1007\/s00259-025-07167-5","volume":"52","author":"W Huang","year":"2025","unstructured":"Huang W, Zhang Y, Xiao X, Yang Q, Mixdorf JC, Sun X, et al. ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [(64)Cu]Cu-NOTA-Trodelvy-F(ab\u2019)(2). Eur J Nucl Med Mol Imaging. 2025;52:3223\u201337. https:\/\/doi.org\/10.1007\/s00259-025-07167-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7796_CR25","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1007\/s00259-025-07326-8","volume":"52","author":"D Jiang","year":"2025","unstructured":"Jiang D, Chu Z, Wu Y, Zhang Y, Liu Y, Ge Q, et al. [(68)Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors. Eur J Nucl Med Mol Imaging. 2025;52:4547\u201357. https:\/\/doi.org\/10.1007\/s00259-025-07326-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7796_CR26","doi-asserted-by":"publisher","unstructured":"Chen H, Zhao L, Pang Y, Shi J, Gao H, Sun Y, et al. 68Ga-MY6349 PET\/CT imaging to assess Trop2 expression in multiple types of cancer. J Clin Investig. 2024;135. https:\/\/doi.org\/10.1172\/jci185408.","DOI":"10.1172\/jci185408"},{"key":"7796_CR27","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.2967\/jnumed.124.268751","volume":"65","author":"W Huang","year":"2024","unstructured":"Huang W, Cao M, Wu Y, Zhang Y, An S, Pan X, et al. Immuno-PET\/CT imaging of Trop2 with [(18)F]AlF-RESCA-T4 differentiates lung cancer from inflammation. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2024;65:1904\u201310. https:\/\/doi.org\/10.2967\/jnumed.124.268751.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"7796_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07326-8","author":"D Jiang","year":"2025","unstructured":"Jiang D, Chu Z, Wu Y, Zhang Y, Liu Y, Ge Q, et al. [(68)Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07326-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7796_CR29","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s12282-022-01389-3","volume":"29","author":"J Zhu","year":"2022","unstructured":"Zhu J, Wu W, Togashi Y, Taira Nihira N, Johmura Y, Zhu D, et al. Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired Tamoxifen resistance. Breast Cancer. 2022;29:1076\u201387. https:\/\/doi.org\/10.1007\/s12282-022-01389-3.","journal-title":"Breast Cancer"},{"key":"7796_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","volume":"66","author":"M Shastry","year":"2022","unstructured":"Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. Breast. 2022;66:169\u201377. https:\/\/doi.org\/10.1016\/j.breast.2022.10.007.","journal-title":"Breast"},{"key":"7796_CR31","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","volume":"15","author":"HU Balinda","year":"2024","unstructured":"Balinda HU, Kelly WJ, Kaklamani VG, Lathrop KI, Canola MM, Ghamasaee P, et al. Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial. Nat Commun. 2024;15:6707. https:\/\/doi.org\/10.1038\/s41467-024-50558-9.","journal-title":"Nat Commun"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07796-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:08:41Z","timestamp":1779422921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07796-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7796"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07796-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the ethics committee of Huashan Hospital Institutional Review Board (HIRB), Fudan University, China. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}